Abbott Concludes Former Employees’ Allegations Concerning Michigan Formula Plant ‘Unfounded’

Firm Plans Spending $500M To Build US Facility To Boost Formula Production

Abbott’s Q3 worldwide sales of formula and other pediatric nutritionals were down 24.8% on reported basis. It plans spending $500m on a new formula facility after finding the US “would benefit from more manufacturing capacity and redundancy.”

• Source: Shutterstock

Abbott is done investigating a former employee’s allegations about quality-control problems at its Michigan infant formula plant but impacts on revenues from temporarily shutting down the facility aren’t done with the firm.

Another impact from the shutdown and Abbott’s related recall of three of its major formula brands the firm announced with its lasts results on 19 October is a plan to invest

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business